• Users Online: 741
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Contacts Login 

 Table of Contents  
Year : 2016  |  Volume : 36  |  Issue : 2  |  Page : 78-80

An unusual case of primary prostatic extragastrointestinal stromal tumor

1 Department of Internal Medicine, Tri-Service General Hospital, National Defence Medical Centre, Taipei, Taiwan
2 Department of Pathology, Tri-Service General Hospital, National Defence Medical Centre, Taipei, Taiwan
3 Department of Surgery, Division of Urological Surgery, Tri-Service General Hospital, National Defence Medical Centre, Taipei, Taiwan
4 Department of Internal Medicine, Division of Haematology and Oncology, Tri-Service General Hospital, National Defence Medical Centre, Taipei, Taiwan

Date of Submission24-Dec-2015
Date of Decision23-Feb-2016
Date of Acceptance08-Mar-2016
Date of Web Publication2-May-2016

Correspondence Address:
Ching-Liang Ho
Department of Internal Medicine, Division of Haematology and Oncology, Tri-Service General Hospital, National Defence Medical Centre, Taipei
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1011-4564.181524

Rights and Permissions

Extragastrointestinal stromal tumors (EGISTs) originate from several anatomic sites, except the digestive system. We describe an early prostatic EGIST case with lower urinary tract symptoms and a palpable lesion on digital examination. The patient received transrectal ultrasonography-guided biopsy of the prostate, and the pathological finding demonstrated positive staining for DOG-1 and CD117. Treatment included only imatinib, which shrank the tumor and led to complete remission. Because of enlarged prostate volume with tumor progression, the initial common manifestations are lower urinary tract symptoms. Surgical resection is the recommended management, particularly in bulky lesions. However, imatinib still plays an important role in long-term therapy. We also review the associated reported cases of prostatic EGISTs.

Keywords: Extragastrointestinal stromal tumor, prostate, imatinib

How to cite this article:
Chang CF, Wen LW, Wu ST, Ho CL. An unusual case of primary prostatic extragastrointestinal stromal tumor. J Med Sci 2016;36:78-80

How to cite this URL:
Chang CF, Wen LW, Wu ST, Ho CL. An unusual case of primary prostatic extragastrointestinal stromal tumor. J Med Sci [serial online] 2016 [cited 2021 Jul 31];36:78-80. Available from: https://www.jmedscindmc.com/text.asp?2016/36/2/78/181524

  Introduction Top

Gastrointestinal stromal tumor (GIST) is a type of soft tissue tumor occurring primarily in the digestive system. GISTs arising from the outside of the alimentary tract are grouped into extragastrointestinal stromal tumors (EGISTs), and prostate is a rare presentation site.[1] The reported EGISTs are diagnosed by immunohistochemical staining, including CD34, CD117, and DOG-1. In particular, CD117 is strongly marked with the interstitial cells of Cajal, and GIST is believed to be transformed from the interstitial cells of Cajal. These cells stimulate smooth muscle contraction in the alimentary tract. It has been hypothesized that interstitial cells of Cajal could be found in the prostate and lead to EGISTs.

  Case Report Top

A 60-year-old male presented with symptoms of hesitancy, weak urine stream, and nocturia for 1 year. Digital examination showed a distinctive 2-cm hard mass fixed in the prostate. The prostate was within Grade I–II enlargement and had a firm consistency with the prostate-specific antigen level was measured to be 1.84 ng/mL. Meanwhile, colonoscopy revealed a small 0.2 cm × 0.2 cm polyp that was 20 cm away from the anal verge. Magnetic resonance imaging (MRI) of the abdomen revealed a nodular lesion measuring approximately 1.8 cm between the rectum and prostate [Figure 1]. He underwent transrectal ultrasonography of the prostate, and a hypoechoic nodule measuring 1.8 cm × 1.1 cm in size was identified within the peripheral zone in the left lobe of the prostate [Figure 2]. A biopsy was performed, which confirmed the pathological diagnosis of GIST based on the prostatic tissue biopsy strips. The immunohistochemical findings were positive for c-kit and DOG-1 [Figure 3], with a low Ki-67 proliferative index (5%). A whole-body bone scan showed no evidence of bony metastasis. He refused to undergo radical prostatectomy and agreed to take imatinib (400 mg/day) after consultation with the oncologist. During follow-up, an MRI of the pelvis showed remarkably complete remission 1 year later, and there was no tumor progression or metastasis. We rechecked the findings using digital examination, which showed that the palpable lesion diminished. The lower urinary tract symptoms were also well improved.
Figure 1: An magnetic resonance imaging of the abdomen showed a nodular lesion about 1.8 cm in size between the rectum and prostate with persistent enhancement during the dynamic study (a); compared with the magnetic resonance imaging taken 1-year earlier, a nodular lesion within the prostate could not be identified at follow-up (b)

Click here to view
Figure 2: A hypoechoic nodule 1.8 cm × 1.1 cm in size was fixed within the left lobe peripheral zone of the prostate in the findings of transrectalultrasonography

Click here to view
Figure 3: Tissue strips were composed of hypercellularity and bland-looking spindle tumor cell. The junction between tumour cell and prostatic stroma were distinctive in (a and b). Diffuse CD117 (c) and DOG-1 (d) staining on needle prostate biopsy of extragastrointestinal stromal tumor

Click here to view

  Discussion Top

EGISTs are mesenchymal tumors that include smooth muscle tumors, fibromatosis, and neural tumors and commonly occur in the omentum, mesentery, and retroperitoneum; however, primary prostatic EGISTs are relatively rare.[2] A majority of the patients are diagnosed at a late stage when they exhibit excessive tumor growth and lower urinary tract symptoms. Transrectal ultrasound-guided prostate biopsy is the common diagnostic procedure initially, but the biopsy strips may occasionally get mixed with the rectal tissues when the needle passes through the rectal wall. Hence, colonoscopy is an essential procedure to exclude gastrointestinal lesions, and pathological findings can further clarify the diagnosis.

It is believed that GIST is transformed from the interstitial cell of Cajal, which is an important pacemaker cell that regulates smooth muscle contraction in the gastrointestinal tract. The interstitial cells of Cajal or related stem cell-like precursors are positive for CD34 or CD117 in the immunohistochemical staining. The diagnosed prostatic EGISTs show similar immunohistochemical features to those of GISTs; however, there is no strong evidence that all EGISTs correlate with the transformation of the interstitial cells of Cajal. Gevaert et al. showed that cells resembling the interstitial cells of Cajals are present in the subepithelial area, which is the area between the epithelial cells and smooth muscle bundles of the prostate stroma space. These interstitial cells are immunoreactive to CD34. In addition, positive immunohistochemical staining for c-kit (also known as CD117) compared to mast cells was found in the prostate stroma.[3] These findings might be correlated with the potential risks of prostatic EGISTs. CD117 is absolutely an important marker for diagnosis, and higher immunohistochemical labeling for CD117 indicates a greater therapeutic response in GIST cases.[4] In those cases with a weak or negative staining for CD117, DOG-1 is a reliable antibody that could be used in the diagnosis of GISTs and EGISTs. The Ki-67 proliferative index is a nonlocation-specific prognostic factor. The higher value of Ki-67 in the present case (cut-off point is 6%) indicates a poor prognosis, and it has more statistical significance than the original tumor site.[5]

The therapeutic strategy for prostatic EGISTs depends on individualized conditions and is applied based on the therapeutic management of GISTs. Imatinib, the target therapy for GISTs and a selective tyrosine kinase inhibitor, primarily acts on tyrosine kinase: Abl, c-kit, and platelet-derived growth factor receptor. Due to its specific mechanism, imatinib 400 mg/day is the major treatment for those cases with prostatic EGISTs, wherein improved outcomes have been reported.[6],[7],[8] However, during long-term imatinib use, tumor resistance is a concern and the therapeutic response in advanced stages is also controversial. Hence, surgery is recommended as the first-line of treatment because bulky lesions exhibit poor responses to targeted therapies and have a higher likelihood of secondary recurrence. Blanke et al. speculated that there was no correlation between imatinib use duration and the possibility of secondary recurrence.[9]

Clinicians should be aware of prostatic EGISTs in clinical practice among differential diagnoses. Surgical resection is the major treatment in bulky lesions. While considering the surgical side effects and the patient's quality of life, administrating imatinib to patients with early prostatic EGISTs may be beneficial compared to immediate surgical intervention. The duration of imatinib use has no correlation with tumor recurrence but has a significant effect on the overall survival rate.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

  References Top

Reith JD, Goldblum JR, Lyles RH, Weiss SW. Extragastrointestinal (soft tissue) stromal tumors: An analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol 2000;13:577-85.  Back to cited text no. 1
Yinghao S, Bo Y, Xiaofeng G. Extragastrointestinal stromal tumor possibly originating from the prostate. Int J Urol 2007;14:869-71.  Back to cited text no. 2
Gevaert T, Lerut E, Joniau S, Franken J, Roskams T, De Ridder D. Characterization of subepithelial interstitial cells in normal and pathological human prostate. Histopathology 2014;65:418-28.  Back to cited text no. 3
Patnayak R, Jena A, Parthasarathy S, Prasad PD, Reddy MK, Chowhan AK, et al. Primary extragastrointestinal stromal tumors: A clinicopathological and immunohistochemical study – A tertiary care center experience. Indian J Cancer 2013;50:41-5.  Back to cited text no. 4
[PUBMED]  Medknow Journal  
Belev B, Brcic I, Prejac J, Golubic ZA, Vrbanec D, Božikov J, et al. Role of Ki-67 as a prognostic factor in gastrointestinal stromal tumors. World J Gastroenterol 2013;19:523-7.  Back to cited text no. 5
Van der Aa F, Sciot R, Blyweert W, Ost D, Van Poppel H, Van Oosterom A, et al. Gastrointestinal stromal tumor of the prostate. Urology 2005;65:388.  Back to cited text no. 6
Ou Z, Cao Z, He Y, Tang D. Diagnosis and multimodal therapy for extragastrointestinal stromal tumor of the prostate: A case report. Exp Ther Med 2013;6:378-380.  Back to cited text no. 7
Herawi M, Montgomery EA, Epstein JI. Gastrointestinal stromal tumors (GISTs) on prostate needle biopsy: A clinicopathologic study of 8 cases. Am J Surg Pathol 2006;30:1389-95.  Back to cited text no. 8
Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26:620-5.  Back to cited text no. 9


  [Figure 1], [Figure 2], [Figure 3]


Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  In this article
Case Report
Article Figures

 Article Access Statistics
    PDF Downloaded162    
    Comments [Add]    

Recommend this journal